• We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. Apr 1, 1997; 99(7): 1478–1483.
PMCID: PMC507966

Hyperexpression of mitogen-activated protein kinase in human breast cancer.

Abstract

Mitogen-activated protein (MAP) kinases act as transducers of extracellular signaling via tyrosine kinase-growth factor receptors and G-protein-linked receptors to elements regulating transcription. The activity, abundance, and localization of MAP kinase was investigated in normal and malignant neoplasia of the breast. In carcinoma of the breast, MAP kinase was heavily phosphorylated on tyrosyl residues and its activity elevated 5-10-fold over benign conditions, such as fibroadenoma and fibrocystic disease. By in situ reverse transcription-polymerase chain reaction, hyperexpression of MAP kinase mRNA can be localized to malignant, epithelial cells. Metastatic cells within involved lymph nodes of patients with breast cancer also display hyperexpression of MAP kinase. In spite of persistent activation via phosphorylation, MAP kinase expression is upregulated 5-20-fold and this hyperexpression may be a critical element to initiation as well as the metastatic potential of various forms of human breast cancer.

Full Text

The Full Text of this article is available as a PDF (18M).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Wingo PA, Tong T, Bolden S. Cancer statistics, 1995. CA Cancer J Clin. 1995 Jan-Feb;45(1):8–30. [PubMed]
  • Dickson RB, Salomon DS, Lippman ME. Tyrosine kinase receptor--nuclear protooncogene interactions in breast cancer. Cancer Treat Res. 1992;61:249–273. [PubMed]
  • Blenis J. Signal transduction via the MAP kinases: proceed at your own RSK. Proc Natl Acad Sci U S A. 1993 Jul 1;90(13):5889–5892. [PMC free article] [PubMed]
  • Cobb MH, Goldsmith EJ. How MAP kinases are regulated. J Biol Chem. 1995 Jun 23;270(25):14843–14846. [PubMed]
  • Janes PW, Daly RJ, deFazio A, Sutherland RL. Activation of the Ras signalling pathway in human breast cancer cells overexpressing erbB-2. Oncogene. 1994 Dec;9(12):3601–3608. [PubMed]
  • Callans LS, Naama H, Khandelwal M, Plotkin R, Jardines L. Raf-1 protein expression in human breast cancer cells. Ann Surg Oncol. 1995 Jan;2(1):38–42. [PubMed]
  • Arteaga CL, Johnson MD, Todderud G, Coffey RJ, Carpenter G, Page DL. Elevated content of the tyrosine kinase substrate phospholipase C-gamma 1 in primary human breast carcinomas. Proc Natl Acad Sci U S A. 1991 Dec 1;88(23):10435–10439. [PMC free article] [PubMed]
  • Gupta SK, Gallego C, Johnson GL, Heasley LE. MAP kinase is constitutively activated in gip2 and src transformed rat 1a fibroblasts. J Biol Chem. 1992 Apr 25;267(12):7987–7990. [PubMed]
  • Moxham CP, George ST, Graziano MP, Brandwein HJ, Malbon CC. Mammalian beta 1- and beta 2-adrenergic receptors. Immunological and structural comparisons. J Biol Chem. 1986 Nov 5;261(31):14562–14570. [PubMed]
  • Nuovo GJ, Forde A, MacConnell P, Fahrenwald R. In situ detection of PCR-amplified HIV-1 nucleic acids and tumor necrosis factor cDNA in cervical tissues. Am J Pathol. 1993 Jul;143(1):40–48. [PMC free article] [PubMed]
  • Nuovo GJ, MacConnell PB, Simsir A, Valea F, French DL. Correlation of the in situ detection of polymerase chain reaction-amplified metalloproteinase complementary DNAs and their inhibitors with prognosis in cervical carcinoma. Cancer Res. 1995 Jan 15;55(2):267–275. [PubMed]
  • Hadcock JR, Malbon CC. Agonist regulation of gene expression of adrenergic receptors and G proteins. J Neurochem. 1993 Jan;60(1):1–9. [PubMed]
  • Brunet A, Brondello JM, L'Allemain G, Lenormand P, McKenzie F, Pagès G, Pouysségur J. Le module MAP kinase: rôle dans le contrôle de la prolifération cellulaire. C R Seances Soc Biol Fil. 1995;189(1):43–57. [PubMed]
  • Brunet A, Pagès G, Pouysségur J. Constitutively active mutants of MAP kinase kinase (MEK1) induce growth factor-relaxation and oncogenicity when expressed in fibroblasts. Oncogene. 1994 Nov;9(11):3379–3387. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles
  • Substance
    Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...